|
Market Research Report
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
|
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff? published by Decision Resources, Inc. in September, 2009. This report consists of 24 Pages and the price starts from US $ 4600.
Abstract
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D
operations - such as creating more entrepreneurial environments modeled upon
biotech companies - increase their productivity? Many major companies are
reorganizing the research branches of their businesses and fi nding creative
ways to partner with biotech companies and with each other to access or
acquire promising technologies and pipelines. Their goal is to reinvigorate
R&D and combat the effects of patent expirations, generics competition, and
other industry pressures.
Questions Answered in This Report
- In recent years, drug developers have invested heavily in various R&D
technologies. Is this investment increasing R&D productivity? What
technology strategies are most promising? What new approaches are
pharmaceutical companies using to access enabling technologies for drug
discovery?
- Pharmaceutical companies are seeking to reinvigorate R&D organizations to
improve productivity. What steps are leading companies taking to change
R&D? What structures and strategies have already been implemented within Big
Pharma R&D organizations? Can pharmaceutical companies replicate the
innovation of biotech companies by reforming R&D?
- Biotech companies are an important source of novel technologies and drug
candidates. How do acquisitions of and collaborations with biotech
companies fi t into Big Pharma' s R&D strategies? How can companies use
business development activities to build up technological capabilities and
pipelines?
- Several Big Pharma companies are charting new territory in early-stage
pharma-pharma dealmaking. Which companies have recently formed innovative
partnerships that include early-stage development? What are the key features
of these arrangements? How do these ventures meet the strategic needs of both
partners?
Scope
- Technology strategies: Use of high-throughput technologies and R&D
productivity, biologics platforms, pharma-pharma ventures for enabling
technology development.
- Organizational structures and strategies: Restructuring R&D,
emulating biotech, case studies of R&D reorganization.
- Building R&D through business development: M&As, collaborations,
R&D strategies.
- Pharma-pharma partnering: Strategic alliances among Big Pharma
companies, Phase I codevelopment collaboration, therapeutic area joint venture.
- Outsourcing R&D: China, India, potential advantages and
disadvantages.
- Outlook for pharmaceutical R&D: Changing business models,
personalized medicine, pursuing novel targets, collaboration, high-throughput
strategies, translational medicine.
Mentioned in This Report
- Adnexus Therapeutics
- Amgen
- AstraZeneca
- BiPar Sciences
- Bristol-Myers Squibb
- Cambridge Antibody Technology
- Coley Pharmaceutical
- CovX Research
- Dyax
- Eli Lilly
- Endra
- Enlight Biosciences
- Exelixis
- Genentech
- GlaxoSmithKline
- GlycoFi
- Johnson & Johnson
- KAI Pharmaceuticals
- Kosan Biosciences
- Medarex
- MedImmune
- Merck
- Nissan Chemical Industries
- Novartis
- Oxford BioMedica
- PDL BioPharma
- Pfi zer
- PureTech Ventures
- Regeneron
- Renovis
- Rinat Neurosciences
- Roche
- Sirtris
- Sanofi -Aventis
- Teijin Pharma
- Wyeth
- Zymogenetics
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Technology Strategies - Will They Pay Off?
- The Industrialization of Drug Discovery
- Biologics Platforms
- Enlight Biosciences: Big Pharma' s Technology Collaboration
- Organizational Structures and Strategies
- GlaxoSmithKline
- Novartis
- Pfi zer
- Sanofi -Aventis
- Building R&D Through Business Development
- Pharma-Pharma Partnering
- AstraZeneca and Merck: Early-Stage Development for Cancer
- GlaxoSmithKline and Pfi zer: A Joint Venture for HIV
- Moving R&D to China and India
- Outlook for Pharmaceutical R&D
Tables
- 1. Top-Selling Biologic Drugs
- 2. Bristol-Myers Squibb' s “String of Pearls” Deals
- 3. GlaxoSmithKline/Pfi zer HIV Joint Venture Portfolio
Figures
- 1. Combined R&D Expense vs. New Molecular Entity Approvals for 15 Top
Pharmaceutical Companies, 2000-2008
- 2. Business Model for Enlight Biosciences
- 3. Simplifi ed Scheme of the Mechanisms of Action of MK-2206 and AZD-6244
|
